• Oruka Therapeutics CEO Lawrence Otto Klein sold 74,999 shares on Sep. 1, 2026 at about $91.81.
• He also acquired 75,000 shares at $7.8 through an employee warrant exercise.
• Directly held common stock fell to 925,580 shares following the transactions.
• Employee warrant holdings rose to 1,553,513 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000907654-26-000087), on September 01, 2026, and is solely responsible for the information contained therein.